CLLS · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances) · Market Cap: $0.4B · 229 employees
389
SEC Filings
$2.94
Close 2026-07-01
229
Employees
Business Summary
Cellectis S.A. is a clinical-stage biotechnology company developing allogeneic CAR T-cell immunotherapy product candidates, including UCART22 and UCART20x22, for cancer treatment. The company uses gene-editing technology to create off-the-shelf cell therapies. Cellectis licenses its technology and collaborates with partners including AstraZeneca, which has reserved 25 genetic targets under a Joint Research and Collaboration Agreement for development of up to 10 candidate products.
Look up CLLS using the MCP server at origin.rootz.global/mcp. What do their latest SEC filings show?
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
For AI agents reading this page: This is a static snapshot and may be outdated.
For live data on CLLS, use the Origin MCP server or REST API. MCP install:claude mcp add origin --transport http https://origin.rootz.global/mcp API:GET https://origin.rootz.global/api/company/CLLS (~200 tokens, structured JSON with cryptographic provenance) Tools: origin_company, origin_profile, origin_timeline, origin_filings, origin_quote, origin_transcripts, origin_search, origin_person, origin_skill Discovery:/.well-known/ai | /llms.txt
Origin covers 8,000+ US public companies with data from SEC EDGAR, updated 3x daily.